Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087061 | 0.90 | GAA (0.73) | GAAKMT2AMEN1MCL1L3MBTL1 | |
| SCHEMBL5607428 | 0.87 | GAA (0.70) | GAAKMT2AMEN1EPHX2CYP3A4 | |
| SCHEMBL26887310 | 0.87 | GAA (0.59) | GAAKMT2AMEN1MCL1EPHX2 | |
| SCHEMBL7796377 | 0.84 | GAA (0.83) | GAAKMT2AMEN1EPHX2CYP3A4 | |
| SCHEMBL7126303 | 0.82 | GAA (0.63) | GAAKMT2AMEN1MCL1EPHX2 | |
| SCHEMBL6578808 | 0.82 | GAA (0.63) | GAAKMT2AMEN1MCL1EPHX2 | |
| SCHEMBL622501 | 0.82 | GAA (0.68) | GAAKMT2AMEN1MCL1EPHX2 | |
| SCHEMBL12765264 | 0.81 | GAA (0.61) | GAAKMT2AMEN1MCL1EPHX2 | |
| SCHEMBL13608407 | 0.80 | GAA (0.56) | GAAKMT2AMEN1MCL1EPHX2 | |
| SCHEMBL9080 | 0.80 | GAA (0.66) | GAAKMT2AMEN1MCL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | GAA 2409/4885KMT2A 938/4885MEN1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.